Metrikler
Yayın
30
Açık Erişim
2
BM Sürdürülebilir Kalkınma Amaçları
Eğitim Bilgileri
2019 - Devam Ediyor
2019 - Devam EdiyorTıpta Yandal Uzmanlık
İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye
2014 - 2019
2014 - 2019Tıpta Uzmanlık
İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye
2008 - 2014
2008 - 2014Lisans
Marmara Üniversitesi, Tıp Fakültesi, Türkiye
Yaptığı Tezler
2019
2019Tıpta Uzmanlık
Enzimli Ortamda Çapraz Karşılaştırma Testi Pozitif Hastalarda Transfüzyon Sonrası Komplikasyonların Retrospektif Değerlendirilmesi
İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
Yabancı Diller
C2 Ustalık
C2 Ustalıkİngilizce
Araştırma Alanları
Tıp
Sağlık Bilimleri
Dahili Tıp Bilimleri
İç Hastalıkları
Hematoloji
Akademik Faaliyetlere Dayalı Araştırma Alanları
Avesis Araştırma Alanları
WoS Araştırma Alanları
Scopus Araştırma Alanları
Akademik Ünvanlar / Görevler
2019 - Devam Ediyor
2019 - Devam EdiyorUzman Dr.
İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
2014 - 2019
2014 - 2019Araştırma Görevlisi Dr.
İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
Makaleler
Tümü (27)
SCI-E, SSCI, AHCI (25)
SCI-E, SSCI, AHCI, ESCI (26)
ESCI (1)
Scopus (26)
TRDizin (4)
2026
20261. Plasma Cell Contamination in Autografts Determined by Dual Quantification Before Cryopreservation and After Thawing Predicts Transplant Outcomes in Multiple Myeloma: A Prospective, Proof-of-Concept Study
Yilmaz U., ELVERDİ T., BAYAR M., ZULFALIYEVA G., Çavuşoğlu M., Ozmen D., et al.
Cerrahpaşa Medical Journal
, sa.1, ss.1-8, 2026 (TRDizin)
2026
20262. Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohort
YILMAZ U., TERZİ DEMİRSOY E., KEKLİK KARADAĞ F., Hatipoglu U., Ulukoylu Menguc M., Pekguc E., et al.
BRITISH JOURNAL OF HAEMATOLOGY
, cilt.208, sa.1, ss.139-148, 2026 (SCI-Expanded, Scopus)
2026
20263. Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world cohort of 1369 patients
YILMAZ U., Dal M. S., Ulaş T., Ateşoğlu E. B., Keklik Karadağ F., Mengüç M. U., et al.
Cancer
, cilt.132, sa.1, 2026 (SCI-Expanded, Scopus)
2025
20254. Clinical Manifestations, Treatment Characteristics and Clinical Outcome in Patients with Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in the Real-World Setting: An Interim Analysis of the Turkish aTTP Registry.
Karakuş S., Bakanay Ş. M., Kalayoğlu Beşişik S., Eşkazan A. E., Ayyıldız O., Gürkan E., et al.
Turkish journal of haematology : official journal of Turkish Society of Haematology
, cilt.42, ss.203-212, 2025 (SCI-Expanded, Scopus, TRDizin)
2025
20255. Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease.
Guliyev M., Tunc A., Yılmaz U., Kucukyurt S., Ozmen D., Elverdi T., et al.
International journal of hematology
, cilt.122, ss.73-82, 2025 (SCI-Expanded, Scopus)
2025
20256. Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m².
Yılmaz U., Erdem Nurcan Ş., Özmen D., Salihoğlu A., Eşkazan A. E., Öngören Ş., et al.
Annals of transplantation
, cilt.30, 2025 (SCI-Expanded, Scopus)
2025
20257. Tight competition for the first-line treatment of Hodgkin’s lymphoma: a comprehensive review of practice-changing developments in recent years
Yılmaz U., Birtaş Ateşoğlu E., Ferhanoğlu B.
Expert Opinion on Biological Therapy
, cilt.25, sa.7, ss.731-747, 2025 (SCI-Expanded, Scopus)
2024
20248. Impact Of Bone Marrow Fibrosis In Multiple Myeloma At Diagnosis and On DIsease Course
AHADZADE A., YILMAZ U., Kaya S. K., ERÇALIŞKAN A., ÖZMEN İBİŞ D., ELVERDİ T., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
, 2024 (SCI-Expanded, Scopus)
2024
20249. Chronic myeloid leukemia in renal transplantation patients in the era of tyrosine kinase inhibitors: A case report and review of the literature
MURT A., Bayram B., YILMAZ U., SEYAHİ N., EŞKAZAN A. E.
NEPHRON
, cilt.148, sa.8, ss.563-568, 2024 (SCI-Expanded, Scopus)
2024
202410. Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?
Yılmaz U., Küçükyurt S., Ar M. C., Eşkazan A. E.
Oncology and therapy
, cilt.12, sa.1, ss.157-161, 2024 (ESCI, Scopus)
2024
202411. Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma
Yılmaz U., Zulfaliyeva G., Güzelli A. N., Özmen D., Elverdi T., Salihoğlu A., et al.
JOURNAL OF CHEMOTHERAPY
, cilt.36, sa.5, ss.403-410, 2024 (SCI-Expanded, Scopus)
2023
202312. Acquired Hemophilia A In Adults: A Multicenter Study from Turkey
Davulcu E. A., DEMİRCİ Z., YILMAZ U., AR M. C., ÜSKÜDAR TEKE H., Karakus V., et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
, cilt.39, sa.1, ss.107-115, 2023 (SCI-Expanded, Scopus)
2022
202213. Diagnosis and Management of Classical Hodgkin Lymphoma During the COVID-19 Pandemic ⁎
Küçükyurt S., Şahin K., Yılmaz U., Erçalışkan A., Özkan Tekin T., Ortaboz D., et al.
Current Problems in Cancer
, cilt.46, sa.6, 2022 (SCI-Expanded, Scopus)
2022
202214. Kikuchi Fujimoto disease as the presenting component of VEXAS syndrome: a case report of a probable association
Yılmaz U., Güner S., Eşkazan T., Demiröz A. S., Kurtuluş G., Bahar F., et al.
CLINICAL RHEUMATOLOGY
, cilt.41, sa.11, ss.3589-3592, 2022 (SCI-Expanded, Scopus)
2022
202215. Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase.
Yılmaz U., Küçükyurt S., Tunç S., Eşkazan A. E.
Frontiers in oncology
, cilt.12, sa.1, ss.994101, 2022 (SCI-Expanded, Scopus)
2022
202216. Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review.
Yılmaz U., Bulan B., Belli Ç., Eşkazan A. E.
Expert review of hematology
, cilt.15, ss.423-429, 2022 (SCI-Expanded)
2022
202217. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
CİVRİZ BOZDAĞ S., CENGİZ SEVAL G., Hindilerden I. Y., Hindilerden F., ANDIÇ N., BAYDAR M., et al.
TURKISH JOURNAL OF HEMATOLOGY
, cilt.39, sa.1, ss.43-54, 2022 (SCI-Expanded, Scopus, TRDizin)
2021
202118. The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience
Kucukyurt S., Şahin K., Yılmaz U., Erçalışkan A., Özkan Tekin T., Ortaboz D., et al.
Blood , cilt.138, sa.Supplement 1, 2021 (SCI-Expanded, Scopus)
2021
202119. Dermatomyositis Associated With Papillary Thyroid Cancer Systematic Review of the Literature and a Case Report
Yilmaz U., Ugurlu S.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
, cilt.27, sa.4, ss.168-172, 2021 (SCI-Expanded, Scopus)
2021
202120. COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey
Yılmaz U., Pekmezci A., Gül Y., Eşkazan A. E.
Turkish journal of haematology : official journal of Turkish Society of Haematology
, cilt.38, ss.79-81, 2021 (SCI-Expanded, Scopus, TRDizin)
2021
202121. An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
YILMAZ U., SALİHOĞLU A., SOYSAL T.
DRUG DESIGN DEVELOPMENT AND THERAPY
, cilt.15, ss.3809-3820, 2021 (SCI-Expanded, Scopus)
2021
202122. COVID-19 presenting with immune thrombocytopenia: A case report and review of the literature
Murt A., Eskazan A. E., Yılmaz U., Ozkan T., Ar M. C.
JOURNAL OF MEDICAL VIROLOGY
, cilt.93, sa.1, ss.43-45, 2021 (SCI-Expanded, Scopus)
2020
202023. Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation
Sengul S., Yılmaz U., Bedir S., Ozgur Y., Oruc K., Durak S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.8, ss.2042-2046, 2020 (SCI-Expanded, Scopus)
2020
202024. Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?
Yilmaz U., Eskazan A. E.
Expert review of hematology
, cilt.13, ss.1035-1038, 2020 (SCI-Expanded, Scopus)
2020
202025. How to treat myelodysplastic syndrome with clinical features resembling Behcet syndrome: a case-based systematic review
Yilmaz U., Ar M. C., Esatoglu S. N., Bavunoglu I., Erzin Y. Z., Hatemi A. İ., et al.
ANNALS OF HEMATOLOGY
, sa.6, ss.1193-1203, 2020 (SCI-Expanded, Scopus)
2020
202026. Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective?
Yilmaz U., EŞKAZAN A. E.
CANCER
, cilt.126, sa.2, ss.256-259, 2020 (SCI-Expanded, Scopus)
2019
201927. Case report of a young patient with transthyretin amyloidosis associated with Gly67Ala mutation.
Salihoglu A., Yildirim S., Ar M. C., Hancer V. S., Bozcan S., Yilmaz U., et al.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
, cilt.26, ss.75-76, 2019 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2022
20221. Retrospective Analysis of Prognostic Factors and Survival in Multiple Myeloma Patients Aged 65 Years or Older at Diagnosis in a Real-Life Setting and a Proposed New Staging System
TUNÇ A., GULIYEV M., Tekin T. O., Kucukyurt S., YILMAZ U., NUHOĞLU KANTARCI F. E., et al.
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, ss.12518-12519, (Özet Bildiri)
Kongre ve Sempozyum Katılımı Faaliyetleri
08 Haziran 2022 - 12 Haziran 2022
08 Haziran 2022 - 12 Haziran 2022EHA
Çalışma Grubu
Vienna-Avusturya
Burslar
2019 - 2022
2019 - 2022